Gustavo Denegri (born March 1937) is an Italian billionaire businessman, the chairman of DiaSorin, an Italian biotechnology company.
Denegri has a bachelor’s degree in chemistry from the University of Turin.
Denegri owns 44% of DiaSorin via IP Investimenti e Partecipazioni, a holding company controlled by his family.
He is married with two children, and lives in Turin, Italy.
Summary
| Gustavo Denegri | |
|---|---|
| Born | March 1937 (age 80) |
| Residence | Turin, Italy |
| Nationality | Italian |
| Alma mater | University of Turin |
| Known for | owner of 44% of DiaSorin |
| Net worth | US $1.61 billion (January 2017) |
| Title | Chairman, DiaSorin |
| Spouse(s) | married |
| Children | 2 |
Gustavo Denegri was bornon 1937 in torino, Italy, Italy. Gustavo Denegri is #1050 in List Billionaires People In The World. Gustavo Denegri is one of few Italian businessmen to have built billion-dollar companies in more than one sector. Trained as a chemist, his first breakthrough came in the auto industry when Gruppo Pro-Ind, a components firm he founded in the 1970s, merged with manufacturer Piaggio, owner of storied two-wheel brands like Vespa and Aprilia. By 1994 Denegri had built Piaggio into a $1.2 billion company; he sold off his majority stake and relinquished his role as chairman. He then moved to private equity through Iniziativa Piemonte, the precursor to today’s Investimenti e Partecipazioni, and made his biggest bet to date. In 2000, Denegri’s Investimenti built a stake in distressed biotech firm DiaSorin, acquiring it from American firm Standard Companies. DiaSorin is now a global player in the field of in vitro diagnostics — tests for diseases and infections — with revenue surpassing $500 million. In August 2016, DiaSorin, through its U.S. facility in Minnesota, was awarded $2.6 million by the U.S. Department of Health and Human Services to develop a test that would allow for early detection of the Zika virus, a mosquito-borne virus known for causing birth defects. Investimenti, run by Denegri’s son Michele, has a diverse portfolio, including medical technology, real estate, and TV production.
Source: